90-day follow-up study for children using RELiZORB
Part of Digestive system, Hormones & metabolism clinical trials.
This study follows children who are already taking RELiZORB to see how it’s going over time and whether it remains safe and tolerable, with effects on nutrient absorption. It doesn’t change treatment—it mainly looks at outcomes during the next 90 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already enrolled in the earlier RELiZORB Phase 3 study
- A parent/legal guardian can read, understand, and sign the consent form
- You can bring the child to all required clinic visits and complete study tasks
- A parent/legal guardian agrees to share health information for the study
- A doctor/investigator does not find significant pancreatic or bile duct problems
- The child’s feeding formula can’t be changed to a kind that won’t work with RELiZORB cartridges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether RELIZORB helps children with short bowel syndrome (SBS), who rely on IV nutrition (and also tube feeding), absorb fats better. It is an open-label study over 90 days, meaning everyone gets the study treatment and outcomes are compared over time.
This trial studies whether the Eclipse XL1 system is safe and may help people with short bowel syndrome, in both children and adults. It will check how well the approach works and watch for side effects over the study period.
This trial tests if crofelemer can reduce diarrhea and fluid loss in people with short bowel syndrome who have a stoma (no colon connection) and need intravenous nutrition or fluids. The goal is to see if it improves gut function and quality of life.
This trial tests a new medicine called PJ009 for people with short bowel syndrome who need intravenous (IV) nutrition support. It aims to help reduce the need for IV nutrition. To join, you must have been dependent on IV nutrition for at least six months and be on a stable schedule.
This study tests whether a medication called RELiZORB can help adults with moderate to severe acute pancreatitis (sudden, severe pancreas inflammation) tolerate nutrition delivered through a feeding tube. If your body is struggling to accept enough nutrition during acute pancreatitis, this trial may help you receive adequate nutrition while you recover.
This study tests whether the RELiZORB device (which helps digest fat in tube feedings) can improve symptoms for patients with pancreatitis and pancreatic enzyme insufficiency who are in the hospital and rely on a feeding tube for most of their nutrition.
Hear when a new Short Bowel Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.